Komal Jhaveri: Inavolisib approval for PIK3CA mutant ER+ metastatic breast cancer
Komal Jhaveri, Clinical Director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center, shared a post on LinkedIn:
“Excited to see Inavolisib approval (Itovebi – pronounced Eye-Tove-Bee) for PIK3CA mutant ER + metastatic breast cancer.
Important to consider testing for PIK3CA mutation in the first line metastatic setting for those who have recurrence on or within 12 months of adjuvant endocrine therapy and to optimize toxicity management strategies.”
Amol Akhade shared about Inavolisib too.
“Inavolesib plus palbociclib plus fulvestrant has got approval by USFDA for ER resistant PIK3CA mutated Hr positive HER2 negative advanced breast cancer.
Some interesting thoughts about this trial Inavo120.
No OS yet. Toxicity issues present.
One more Option for endocrine resistant patients with PIK3CA mutation.”
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023